[email protected]

Name	:	[email protected]
Website	:	Visit Website
Blog	:	Visit Blog
Social Links	:

Best label printers of 2022 | Popular Science

[email protected]20 Oct, 2022Business

Until some wonderful scientist invents a machine to instantly teleport packages around the world, we?re stuck in the era of shipping labels. Whether you?re running a high-volume online store or just trying to keep track of where all your stuff is, a great label printer can make the process much simpler. The best label printers are typically much more efficient than trying to wrestle with an unreliable all-in-one inkjet printer that tries to do everything and succeeds at almost nothing. These purpose-built printers can make the shipping process a lot easier and a whole lot cheaper. Just be sure you know what you?re looking for before taking the printer plunge.

India�s Gennova Working On Omicron-Specific COVID-19 Vaccine � Source

[email protected]24 Feb, 2022News

India?s Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters. The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine. A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in some 70 countries, did not immediately respond to a request for comment.

India's Gennova Working On Omicron-Specific COVID-19 Vaccine

[email protected]24 Feb, 2022News

India's Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters. The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine. A representative for Gennova, a unit of drugmaker Emcure Pharmaceuticals that does business in some 70 countries, did not immediately respond to a request for comment.

Pune-Based Gennova Biopharmaceuticals Developing Vaccine For Omicron: Why This Could Be A Game Chang

[email protected]24 Feb, 2022News

As Omicron rages across India, causing a spike in COVID-19 cases, Pune's Gennova Biopharmaceuticals is developing an Omicron-specific vaccine. The company, according to a spokesperson, has already filed its phase 2 data with Central Drugs Standard Control Organisation (CDSCO). "Gennova Biopharmaceuticals had filed its phase 2 data with CDSCO on Friday. The Omicron specific variant of vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals," news agency ANI quoted the spokesperson of Gennova Biopharmaceuticals as saying. Here?s what we know so far about this new vaccine.

India's Gennova Biopharma developing Omicron-specific Covid vaccine: Sources

[email protected]21 Feb, 2022News

Gennova Biopharmaceuticals, a Pune-based company which is making India's first mRNA vaccine, has submitted phase-2 trial data of its mRNA Covid-19 vaccine. The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will review the data soon. Sources said the company has also developed an Omicron-specific vaccine, which will be tested on humans for efficacy & immunogenicity soon. During his speech at the 76th United Nations General Assembly (UNGA), Prime Minister Narendra Modi had earlier stated that India?s first mRNA vaccine was in the final stages.

Vaccine for Omicron? Gennova Pharma Makes India's 1st Strain-specific Covid Vax, Govt to Review Tria

[email protected]21 Feb, 2022News

Pune-based pharmaceutical manufacturer Gennova Biopharmaceuticals Ltd has almost completed the phase 3 trials of its Covid-19 messenger or mRNA vaccine even as the company has started developing an Omicron-specific vaccine using the same technology. Gennova has developed an mRNA vaccine for the Omicron variant, which will be tested for safety and efficacy for use in humans, a Times of India report said. Messenger RNA or mRNA technology involves the injection of a small part of the virus?s genetic code (RNA) to stimulate the recipient?s immune response. It contains instructions for human cells to make proteins that mimic part of the novel coronavirus, spurring the immune system into action. No actual virus is contained in the vaccines.

mRNA vaccine testing for Omicron subject to regulatory approvals: Gennova Biopharmaceutical

[email protected]21 Feb, 2022News

The testing of Gennova Biopharmaceutical's mRNA vaccine for the Omicron variant of COVID-19 is subject to regulatory approvals, the company's official spokesperson informed on Monday. The company spokesperson said, "Omicron specific variant of vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals."Meanwhile, the Pune-based Gennova Biopharmaceuticals has submitted phase 2 data of mRNA vaccine and has also completed the recruitment of phase 3 data.

India's First MRNA COVID-19 Vaccine Specific For Omicron Variant Could Go Into Human Trials Soon

[email protected]14 Feb, 2022News

Pune-based Gennova Biopharmaceuticals which has been developing India's first mRNA COVID-19 vaccine has submitted phase 2 data of its candidate HGCO19 and has also completed the recruitment of phase 3 data. Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) is expected to review the data soon. Gennova Biopharmaceuticals has also developed the mRNA vaccine for the Omicron variant that will be tested on humans for efficacy and immunogenicity starting in February.

India's Gennova Developing Omicron-Specific COVID-19 Vaccine

[email protected]14 Feb, 2022News

India's Gennova Biopharmaceuticals is working on an Omicron-specific mRNA COVID-19 vaccine candidate, it told Reuters on Monday, after a person with direct knowledge of the matter said the product could be ready in a month or two. "The Omicron-specific variant of the vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals," a company spokesperson said in a text message. "We will keep you posted." The source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out.

MRNA Vaccine Testing For Omicron Subject To Regulatory Approvals: Gennova Biopharmaceutical

[email protected]14 Feb, 2022Business

By Shalini Bhardwaj The testing of Gennova Biopharmaceutical's mRNA vaccine for the Omicron variant of COVID-19 is subject to regulatory approvals, the company's official spokesperson informed on Monday. The company spokesperson said, "Omicron specific variant of vaccine is under development and will be ready for human clinical trials, subject to regulatory approvals." Meanwhile, the Pune-based Gennova Biopharmaceuticals has submitted phase 2 data of mRNA vaccine and has also completed the recruitment of phase 3 data.